\
&
Contact us
\
&
Contact us
Published on | 9 months ago
Programmes MSCA MSCAThe European Research Executive Agency (REA) of the European Commission is conducting a survey to gather (anonymous) feedback on the added value of MSCA PhDs, in comparison to other doctoral programmes.
The survey is addressed to principal investigators/supervisors as well as PhD researchers (PhD completed or ongoing) involved in MSCA and non-MSCA funded projects.
This feedback is highly valuable as it will help to improve the MSCA Doctoral Networks programme, which is managed by the REA. It will also feed into the European Commission’s wider policy reflections for the forthcoming period: promoting excellence in doctoral education and training is relevant to their strategic objectives for both the European Research Area (ERA) and the European Education Area (EEA), and contributes to the implementation of the European Strategy for Universities (here and here) .
The survey can be accessed here and the Data Protection Notice here. Please note that it may take up to 1-2 minutes for the survey to load completely. The survey should take approximately 15 minutes to complete. The survey will remain open until 10 November 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
